Q1 2020 13F Holders as of 31 Mar 2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
6,235,531
-
Total 13F shares
-
5,997,060
-
Share change
-
+1,647,462
-
Total reported value
-
$133,825,071
-
Put/Call ratio
-
49%
-
Price per share
-
$22.35
-
Number of holders
-
68
-
Value change
-
+$39,824,964
-
Number of buys
-
46
-
Number of sells
-
25
Institutional Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) as of Q1 2020
As of 31 Mar 2020,
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) was held by
68 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
5,997,060 shares.
The largest 10 holders included
Artemis Investment Management LLP, Ikarian Capital, LLC, FMR LLC, BlackRock Inc., VANGUARD GROUP INC, ACUTA CAPITAL PARTNERS, LLC, DRIEHAUS CAPITAL MANAGEMENT LLC, MASSACHUSETTS FINANCIAL SERVICES CO /MA/, Avidity Partners Management LP, and Nuveen Asset Management, LLC.
This page lists
68
institutional shareholders reporting positions in this security
for the Q1 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.